HONG KONG,� CHINA�- EQS�- 23 July 2019 - A fully integrated
biopharmaceutical company -- Uni-Bio Science Group Limited (the "Company",
together with its subsidiaries, the "Group"; Stock code: 0690.HK) are pleased
to announce that after trading hours , the Group have successfully completed a private placement of HKD
30million of new shares with a new strategic investor. The proceeds from the
fund raising will be used as initial capital to progress three new corporate
development projects towards the next stage, with hopes to further strengthen
the Group's portfolio positioning and build long term value for shareholders.

Mr. Kingsley Leung (Left), Chairman of Uni-Bio
Science Group Limited� at the signing
site

The transaction is subscribed by an investment entity of CHMT
Peaceful Development�Fund Management�Limited, headquartered in Hong
Kong, which is a multi-strategy fund with worldwide investments, in both
private and public markets with Asset Under Management (AUM) more than USD 5 billion.
The Fund focuses on real estates, private equity, new technology and
infrastructure as primary footprint, and it is also actively involved in
corporate finance, cash equities and fixed income investments. After a
comprehensive review of R&D innovation ability, business operation,
corporate governance and positive stock price performance of the group in the
past year, the Fund decided to subscribe to a total of 215,800,000 shares,
which will account for 3.48% of the company's issued equity, with a one year
lockup period.

Mr. Kingsley Leung, Chairman of and Executive Director of
Uni-Bio Science Group Limited said, "We developed a relationship with CHMT
peaceful development fund for over a year and they have performed extensive due
diligence on the Group's business. I am excited they finally pulled the trigger
to invest in us. The timing is impeccable, especially as the Group is about to
launch two new exciting products with billion-dollar potential. I believe CHMT
sees the attractive valuation of the Group, and with their strong network of
hedge funds and banks, they can significantly add value by increasing the
company's share-of-voice in the capital markets. This is especially true as
many secondary market investors are interested in looking at pre-revenue biotechs
after the approval of the chapter 18A listing rule of the HKEX last year. I
hope to work more closely with CHMT to share the Group's story to more
sophisticated investors".

About Uni-Bio Science Group Limited

Uni-Bio Science Group
Limited is principally engaged in the research and development, manufacture and
distribution of pharmaceutical products. The research and development center is
fully equipped with a complete system for the development of
genetically-engineered products with a pilot plant test base which is in line
with NMPA requirements. The Group also has two GMP manufacturing bases in
Beijing and Shenzhen. The Group is focused on the development of novel
treatments and innovative drugs addressing the therapeutic areas of endocrine as
diabetes and osteoporosis, ophthalmology and dermatology.

�

Uni-Bio Science Group
Limited was listed on the Main Board of the Hong Kong Stock Exchange on
November 12, 2001. Stock code: 0690.